Literature DB >> 3286510

Bactericidal activity of ciprofloxacin, norfloxacin and ofloxacin in serum and urine after oral administration to healthy volunteers.

H J Zeiler1, D Beermann, W Wingender, D Förster, P Schacht.   

Abstract

A 200 mg oral dose of ciprofloxacin, norfloxacin or ofloxacin was administered to six healthy male volunteers in a three way cross-over study in order to examine the kinetics in humans in relation to the bactericidal activity in serum and urine. Serum concentrations for ciprofloxacin were similar to norfloxacin and lower than ofloxacin. Despite this fact, ciprofloxacin showed the highest serum bactericidal titers compared to norfloxacin and ofloxacin when serum-resistant Escherichia coli C14 was used as a test organism. These results correlate with observations from timekill curve studies in human whole blood, where ciprofloxacin showed superior bactericidal activity compared to norfloxacin or ofloxacin. The amounts of unchanged drug excreted in urine (48 h period) were found to be 35%, 24% and 77% for ciprofloxacin, norfloxacin and ofloxacin respectively, indicating different excretion kinetics. The volumes of urine excreted in the different collection periods were comparable for the three drugs tested. Mean urine concentrations for ciprofloxacin were higher during the 0 to 4 h collection periods, whereas ofloxacin was excreted into the urine over a longer time period. Measurements of urine bactericidal activity showed that ciprofloxacin had the highest titers during the early collection periods, whereas the prolonged excretion of ofloxacin did not result in higher urine bactericidal titers, compared to ciprofloxacin.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3286510     DOI: 10.1007/bf01650502

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  21 in total

1.  Influence of pH and human urine on the antibacterial activity of ciprofloxacin, norfloxacin and ofloxacin.

Authors:  H J Zeiler
Journal:  Drugs Exp Clin Res       Date:  1985

2.  Antibacterial activity in serum and urine as a therapeutic guide in bacterial infections.

Authors:  J Klastersky; D Daneau; G Swings; D Weerts
Journal:  J Infect Dis       Date:  1974-02       Impact factor: 5.226

3.  Pharmacokinetics and tissue penetration of ciprofloxacin.

Authors:  B Crump; R Wise; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

4.  The bactericidal activity in serum and its prognostic clinical value.

Authors:  J Klastersky
Journal:  Infection       Date:  1983       Impact factor: 3.553

5.  In-vitro studies with ciprofloxacin, a new 4-quinolone compound.

Authors:  D S Reeves; M J Bywater; H A Holt; L O White
Journal:  J Antimicrob Chemother       Date:  1984-04       Impact factor: 5.790

6.  The in vitro and in vivo activity of ciprofloxacin.

Authors:  H J Zeiler; K Grohe
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

7.  In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.

Authors:  A Bauernfeind; C Petermüller
Journal:  Eur J Clin Microbiol       Date:  1983-04       Impact factor: 3.267

8.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

9.  Tissue distribution of ciprofloxacin following oral and intravenous administration.

Authors:  A Dalhoff; H U Eickenberg
Journal:  Infection       Date:  1985 Mar-Apr       Impact factor: 3.553

10.  The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin.

Authors:  D C Brittain; B E Scully; M J McElrath; R Steinman; P Labthavikul; H C Neu
Journal:  J Clin Pharmacol       Date:  1985-03       Impact factor: 3.126

View more
  10 in total

Review 1.  Correlation between pharmacokinetics, pharmacodynamics and efficacy of antibacterial agents in animal models.

Authors:  A Dalhoff; U Ullmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-07       Impact factor: 3.267

Review 2.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

3.  Pharmacodynamic effects of amoxicillin versus cefotaxime against penicillin-susceptible and penicillin-resistant pneumococcal strains: a phase I study.

Authors:  L Aguilar; J Rosendo; I P Balcabao; M Martín; M J Giménez; J Frías; J Prieto
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

4.  Suspicion of quinolone active metabolite following discrepancy between predicted and experimental urine bactericidal activities.

Authors:  L Aguilar; M J Giménez; J Costa; R Dal-Ré; J Prieto
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

5.  Ex vivo antibacterial properties of rufloxacin compared with those of norfloxacin in a study with healthy volunteers.

Authors:  L Aguilar; I P Balcabao; P Salvá; M Martín; J Costa; J Prieto; R Dal-ré
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

6.  Comparative serum bactericidal activities of three doses of ciprofloxacin administered intravenously.

Authors:  M Dan; F Poch; C Quassem; R Kitzes
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

Review 7.  Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections.

Authors:  S V Onrust; H M Lamb; J A Balfour
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

8.  Single-dose rufloxacin versus 3-day norfloxacin treatment of uncomplicated cystitis: clinical evaluation and pharmacodynamic considerations.

Authors:  G Del Río; F Dalet; L Aguilar; J Caffaratti; R Dal-Ré
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

9.  Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers.

Authors:  D Israel; J G Gillum; M Turik; K Harvey; J Ford; H Dalton; M Towle; R Echols; A H Heller; R Polk
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

10.  Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers.

Authors:  K G Naber; U Theuretzbacher; M Kinzig; O Savov; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.